HOME >> BIOLOGY >> NEWS
LA BioMed Medical/Research Briefs, July/August 2004

  • LA BioMed Supports Stem Cell Initiative
  • Ethnic Breast Cancer?
  • A Periodic Table For Biology

    La BioMed Supports Stem Cell Initiative

    In coalition with major health and business groups throughout California, LA BioMed has indicated its support for the California Stem Cell Bond Issue Initiative that recently qualified for November's ballot. The initiative will allocate money from a $3 billion bond to fund promising, California-based stem cell research.

    The initiative will distribute an average of $295 million per year over a 10-year period to fund stem cell research at California's universities and other advanced medical research facilities. It will fund all aspects of stem cell therapy development from basic research through clinical trials to the actual delivery of therapies to patients.

    Kenneth P. Trevett, President and CEO of LA BioMed, recently issued the following statement about the initiative:

    The stem cell initiative is a necessary step in the pursuit of scientific research because federal funding for stem cell research has been limited. Unquestionably, stem cell therapy is potentially the most important medical advance since the discovery of antibiotics. This critically important statewide initiative closes the federal funding gap and sets a new state model for advancing scientific research. From an economic standpoint, California will benefit from patents and royalties that result from the research. Construction of research facilities and new research jobs will generate millions of dollars in new tax revenues for California. More importantly, if stem cell research results in a single cure that reduces healthcare costs by just one percent, it would pay for itself several times over during the following decade and save lives along the way.

    Mr. Trevett is available to speak the merits of the stem cell initiative. To contact him, telephone or e-mail the Communicatio
    '"/>



  • Contact: David Feuerherd
    df@issuesmanagement.com
    310-215-0234
    Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
    30-Jul-2004


    Page: 1 2 3

    Related biology news :

    1. BioMed Central to consult funders and librarians over Open Access payment model
    2. BioMed Central explodes Open Access myths
    3. The Scientist and BioMed Central come together to publish high-impact magazine
    4. BioMed Central is pleased to announce the publication of Sydney Brenners autobiography
    5. BioMed Central to deposit e-journals with the British Library
    6. BioMed Central to consider charging authors for paper submissions
    7. Get Research on the move with BioMed Central
    8. BioMed Central to launch at microbiology meeting
    9. BioMed Central to free scientists and clinical researchers from copyright restrictions

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: BioMed Medical Research Briefs July August

    (Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
    (Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
    (Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
    Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
    (Date:7/1/2015)... YORK , July 1, 2015  UCB, ... G ), a global leader in designing, transforming, ... Aecus Innovation Award in recognition of their close ... efficiencies in UCB,s global business services (GBS) finance ... service providers and clients that work together effectively ...
    (Date:6/30/2015)... WASHINGTON , June 30, 2015  NASA astronaut ... launch next month on his first mission to the ... interviews from 8 to 9 a.m. EDT Tuesday, July 7. ... Center in Star City, Russia . The ... on NASA Television highlighting his mission training. To ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Noblis, ... government, announced in a paper published this week in the scientific journal Viruses ... the diagnostic techniques currently used to detect the Ebola virus. Noblis worked with ...
    (Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
    Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
    Cached News: